135 results about "Serum lipid levels" patented technology

The invention relates to ackermania muciniphila Akk21 with hypoglycemic capacity and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides an ackermania muciniphila strain Akk21 with a blood sugar reducing capability. The preservation number of the ackermania muciniphila strain Akk21 is CCTCC (China Center for Type Culture Collection) NO: M 20242779. The invention also provides hypoglycemic drugs, functional food for promoting lead excretion, health care products and a method for preventing and treating lead / arsenic pollution based on the strain Akk21. The Ackermania muciniphila Akk21 has excellent lead and arsenic tolerance and hypoglycemic capacity, can effectively reduce the blood lipid level of mice with type II diabetes, has a remarkable reduction effect on inflammation of the whole body of the mice, and can remarkably reduce the number of harmful flora in the intestinal tract by increasing the abundance of effective flora in the intestinal tract, so that the content of the harmful flora in the intestinal tract is reduced, and the content of the harmful flora in the intestinal tract is reduced. The species diversity and abundance of intestinal flora are improved.

The invention discloses a lactobacillus plantarum strain from healthy people in a cold region and application of the lactobacillus plantarum strain. The lactobacillus plantarum strain is named as PL-H1, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.22286. The lactobacillus plantarum PL-H1 screened by the invention can obviously relieve the disease index, intestinal canal pathological change, inflammatory response and the like of an inflammatory bowel disease (IBD) model mouse. Moreover, compared with a standard strain WCSF1, the strain has the high metabolism characteristic of tryptophan and the function of adjusting the metabolism of IBD host intestinal tryptophan, and the curative effect of preventing and treating IBD is more remarkable. In addition, the lactobacillus plantarum strain PL-H1 can also improve the liver lipid accumulation and NAFLD activity of MCD fed mice, improve the blood lipid level and liver injury of the MCD fed mice and prevent liver fibrosis of the MCD fed mice, can be used for preventing and treating fungal infection related diseases, and is good in safety.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention provides a cardiovascular and cerebrovascular disease risk prediction method and system, and relates to the technical field of data processing.The method comprises the steps that real-time physiological parameters of a target user are obtained, and the real-time physiological parameters comprise the ambulatory blood pressure fluctuation rate, the serum lipoprotein level, the heart rate variability frequency domain index and the sleep apnea hypopnea index; the method comprises the following steps: preprocessing real-time physiological parameters, extracting instantaneous waveform features of blood pressure signals by adopting wavelet transform, and extracting features related to health conditions, including blood pressure level, blood fat level, blood sugar level, electrocardiogram abnormal indexes and cardiac ultrasound abnormal indexes, to form a feature vector set; according to the method, the real-time physiological parameters are acquired, the feature vector set is formed through preprocessing, the krill swarm algorithm is used for optimization, the three-level fusion model is constructed, finally, the cardiovascular and cerebrovascular disease risk degree of the target user is accurately evaluated, early warning information is output, and the accuracy and timeliness of cardiovascular and cerebrovascular disease risk prediction are effectively improved.

The invention belongs to the technical field of natural medicines, and particularly discloses a lipase inhibitor with a specific structure as well as a preparation method and application thereof, the inhibitor is derived from grape leaves and contains C6-C3-C6, 1, 2-benzopyrone, diphenyl ethylene and a phenolic hydroxyl structure, and the lipase inhibitor is a lipase inhibitor with a specific structure. Comprising the following components in percentage by mass: 72.1 to 97.5 percent of flavonoids, 2.5 to 5.1 percent of coumarins, 2.0 to 3.2 percent of stilbenes and 5.1 to 8.3 percent of phenolic acids. According to the lipase inhibitor with the specific structure as well as the preparation method and the application of the lipase inhibitor, the inhibitor can inhibit secretion of lipase, prevent fat from being decomposed into absorbable free fatty acid and monoacylglycerol, and reduce fat absorption; the total cholesterol and the low-density lipoprotein cholesterol are reduced, the blood fat level is improved, and the composition can be applied to preparation of health-care products, functional foods, sports nutritious foods and formula foods for special medical purposes.

The invention discloses a blood fat reducing complex microbial inoculant and application thereof, and belongs to the technical field of medicines. The composite bacterial agent is prepared by compounding pediococcus acidilactici freeze-dried powder and lactococcus gasseri freeze-dried powder, the active bacteria in the pediococcus acidilactici freeze-dried powder are pediococcus acidilactici CICC 20720, and the active bacteria in the lactococcus gasseri freeze-dried powder are lactococcus gasseri CICC 21038. The invention also discloses a preparation method of the composite bacterial agent, and the composite bacterial agent is prepared by compounding the pediococcus acidilactici freeze-dried powder and the lactococcus gasseri freeze-dried powder, the active bacteria in the pediococcus acidilactici freeze-dried powder are pediococcus acidilactici CICC 20720, and the active bacteria in the lactococcus gasseri freeze-dried powder are pediococcus gasseri CICC 21038. The mass ratio of the pediococcus acidilactici freeze-dried powder to the lactococcus gasseri freeze-dried powder in the complex microbial inoculant is (1-3): (1-3). Tests show that the complex microbial inoculant prepared by the invention can significantly reduce the blood fat level in serum and also has the effect of improving hypothyroidism.

This invention provides a *Lactobacillus plantarum* LN-Lp1 strain, its applications, products, and methods, belonging to the field of probiotic technology. The *Lactobacillus plantarum* LN-Lp1 strain has the accession number CGMCC 33158. This LN-Lp1 strain was deposited on December 23, 2024, at the China General Microbiological Culture Collection Center, located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. Based on this strain, this invention also provides its uses and related products. This LN-Lp1 strain exhibits strong resistance to simulated gastric-intestinal stress and good intestinal adhesion and colonization potential. The *Lactobacillus plantarum* LN-Lp1 of this invention has excellent weight-loss effects, improving lipid metabolism and lowering blood lipid levels.

The invention discloses a composition with effects of losing weight and reducing blood fat. Every 100g of the composition comprises the following components and contents: (1) 10-30mg of adiponectin functional fragments; (2) 5 to 15 mg of PCSK9 inhibitory peptide; (3) 1-5 g of a radix puerariae extract; (4) 1-3 g of garcinia cambogia extract; (5) 0.5-2 g of a green coffee bean extract; (6) 1 to 3g of microencapsulated fish oil; (7) 0.5 to 1g of chitosan; and 5 to 10 g of erythritol. Through the synergistic effect of various bioactive components, the composition can effectively reduce fat accumulation and reduce the blood fat level, and meanwhile has good taste and use convenience. The composition disclosed by the invention provides an innovative solution for losing weight and reducing blood fat, and has potential clinical and commercial application values.

The invention discloses a highly efficient cholesterol-lowering Lactobacillus paracasei I MAUJBC1 and its application, and relates to the technical field of functional microorganisms. The strain disclosed in the invention can alleviate weight gain caused by a high-fat diet, improve elevated blood lipid levels; reduce the expression level of cholesterol synthesis genes in the liver; significantly increase the expression level of cholesterol metabolism genes in the liver, and play a cholesterol-lowering role; and increase the abundance of beneficial bacteria in the intestinal flora, effectively improve the intestinal flora disorder caused by a high-fat diet, and play a role in alleviating hyperlipidemia.

The invention mainly relates to a composition for reducing fat and losing weight as well as a preparation method and application thereof, and belongs to the technical field of biology. The composition comprises 30-60 parts of cordyceps flower sporocarp particles, 5-20 parts of morchella sporocarp particles, 10-25 parts of tartary buckwheat powder, 10-25 parts of a mulberry leaf water extract, 5-21 parts of a rhizoma polygonati water extract and 1-6 parts of a cassia seed water extract. The raw materials are mixed to obtain the composition. The composition can improve the blood fat level of hyperlipidemia, inhibit weight increase, reduce the volume of white fat cells, inhibit liver lipid deposition, reverse liver tissue and liver function damage, effectively reduce lipid and lose weight, and play a role in treating hyperlipidemia, obesity and fatty liver.

The present application relates to a kind of pharmaceutical composition for treating type 2 diabetes and its application.The pharmaceutical composition includes icariin, hydroxymethyl coumarin and cinnamaldehyde, by three-component synergistic effect, simultaneously act on insulin resistance, pancreatic beta cell apoptosis and systemic metabolic inflammation three type 2 diabetes core pathological links, auxiliary reduce serum lipid level, and reduce drug-related liver injury risk, good safety.Animal experiment results show that three-drug combination group can effectively reduce blood sugar (decrease about 50%), significantly improve islet structure atrophy, restore hepatocyte index arrangement, reduce glomerular hypertrophy, significantly reduce serum TG and CHOL level (P<0.05) and inflammatory factor IL-6 and TNF-alpha level (P<0.05), and avoid the hepatotoxicity risk (ALT / AST restores to close to normal level) of hydroxymethyl coumarin.The present application is composed of three kinds of natural monomers with clear structure, and has clear components and controllable quality, which provides a more optimal comprehensive treatment strategy for the treatment of type 2 diabetes and its complications.

The application relates to the technical field of microbial fermentation, and discloses a lily fermentation product for improving blood lipid, a preparation method and application thereof. Lily raw materials are taken as fermentation objects, and suitable lactobacillus plantarum fermentation strains are selected to ferment the lily raw materials to obtain a lily fermentation product. Compared with other fermentation products of lactobacillus plantarum, the lily fermentation product of the lactobacillus plantarum of CICC 25125 has more excellent pancreatic lipase inhibition capacity and has the effect of promoting and improving blood lipid levels, thereby providing a better basis for the application of the lily fermentation product in the food field.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

The invention relates to application of lactobacillus acidophilus LA85 in preparation of a product with a blood sugar reducing effect. The brand new application of the lactobacillus acidophilus LA85 strain is developed, namely the lactobacillus acidophilus LA85 strain is used for inhibiting alpha-glucosidase, reducing blood sugar and improving diabetes mellitus, and tests prove that the food intake, the water intake and the urine volume of a mouse with type II diabetes mellitus can be effectively controlled after intervention of the LA85 strain, and the weight value of the mouse is stabilized; the glucose absorption and metabolism capability of diabetic mice is effectively improved, and continuous damage of pancreatic beta cell functions is retarded; the blood lipid level disorder state of the mouse with the type II diabetes mellitus is improved; the inflammation level of a mouse body with type II diabetes mellitus is reduced, and the immunity is improved; and a very good improvement and recovery effect is achieved on abundance and diversity reduction of intestinal flora of the type II diabetes mellitus mice.

The invention relates to application of bifidobacterium animalis subsp. Lactis BLa80 in preparation of a preparation for assisting in improving diabetes mellitus. The bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.22547, and the strain of the bifidobacterium animalis subsp. Lactis BLa80 is a strain of the bifidobacterium animalis subsp. Lactis BLa80 with the preservation number of CGMCC No.22547. The brand new application of the BLa80 strain of the animal bifidobacterium subsp. Lactis is developed, that is, the BLa80 strain is used for improving diabetes, reducing blood sugar or inhibiting alpha-glucosidase, and tests prove that the BLa80 strain can effectively control the food intake, the water intake, the urine volume and the body weight of diabetic mice; the fasting blood-glucose value and the insulin resistance index of a diabetic mouse are reduced; the blood lipid level disorder state of diabetic mice can be improved; the inflammation level of a diabetic mouse body is reduced, anti-inflammatory factors of the mouse body are increased, and the immunity is improved; and the abundance and diversity of intestinal flora of diabetic mice can be improved and recovered.

The application discloses a norchizhiol triterpenoid compound, a preparation method and application thereof. The norchizhiol triterpenoid compound norchizhiol A can be quickly prepared from Ganoderma lucidum. The test proves that the norchizhiol A can inhibit the accumulation of triglyceride in the differentiation process of 3T3L1 preadipocytes. The norchizhiol A can also effectively reduce the weight increase and liver coefficient of high-fat-diet-induced obese mice, regulate the blood lipid level of the obese mice, and significantly intervene and improve the lipoprotein distribution of the body. The compound can be used for preparing anti-obesity and lipid-lowering medicines.

The invention discloses a traditional Chinese medicine composition and application thereof in medicine for improving non-alcoholic fatty liver, and the traditional Chinese medicine composition comprises pulvis fellis suis, pericarpium citri reticulatae, hawthorn and clostridium butyricum. On one hand, potential targets and pathways of drug diseases are determined in network pharmacological analysis, and on the other hand, in an in-vivo experiment, the drug provided by the invention improves obesity and impaired glucose tolerance caused by HFD, reduces the blood fat level, alleviates inflammation, protects the liver, alleviates liver fat vacuole deposition and fatty degeneration, and has a good application prospect. It is proved that the bile acid-hawthorn and pericarpium citri reticulatae-clostridium butyricum combination has prevention and treatment and protection effects on the HFD-induced non-alcoholic fatty liver disease.

The invention discloses an application of a SUMO agonist N106 (the molecular formula is C17H14N4O3S, and the molecular weight is 354.38) in treatment or prevention of metabolic dysfunction related fatty liver disease (MASLD). The early-stage research of the invention finds that the liver SUMOylation level in MASLD clinical specimens and animal models is significantly reduced. In-vivo experiments show that in a high-fat diet induced C57BL / 6 mouse model, N106 (10mg / kg, intraperitoneal injection, once a day) can significantly improve liver lipid deposition and blood fat level of a high-fat diet mouse; in in-vitro experiments, N106 (10 mu M for 24 hours) can effectively reduce lipid droplet accumulation of HepG2 cells. The research reveals that N106 regulates lipid metabolism by activating an SUMOylation modification pathway for the first time, and a novel treatment strategy is provided for MASLD.

The present disclosure relates to a use of Lacticaseibacillus rhamnosus FMBL L23004 CNN in the preparation of a medicament for preventing or treating diabetes mellitus. The Lacticaseibacillus rhamnosus FMBL L23004 CNN was deposited with the China Center for Type Culture Collection (CCTCC) on 26 Jun. 2023 under the accession number CCTCC NO: M 20231099. The Lacticaseibacillus rhamnosus FMBL L23004 CNN strain has the effect of inhibiting the activity of α-glucosidase, α-amylase, and dipeptidyl peptidase IV. Administration of the strain can significantly lower oral glucose tolerance and insulin tolerance in Type 2 Diabetes Mellitus (T2DM) mice, reduce abnormal postprandial blood glucose fluctuations, decrease fasting blood glucose levels, lower fasting insulin levels, reduce blood lipid levels, and alleviate insulin resistance. The strain significantly improves the composition of the gut microbiome, increases the abundance and diversity of beneficial gut bacteria, and reduces the relative abundance of pathogenic bacteria.

The invention belongs to the technical field of biological medicine, and particularly relates to application of LRRFIP1 serving as a bilberry extract to improvement of a target spot of insulin resistance of gestational diabetes mellitus. The insulin resistance of gestational diabetes mellitus is improved by specifically regulating and controlling a PI3K-AKT signal channel and a GLUT4 glucose transporter function in skeletal muscle based on the bilberry extract. The bilberry extract used in the invention is a natural plant source, is high in safety, and is suitable for pregnancy. PI3K-AKT signal channels can be activated at the same time, and insulin resistance and lipid metabolism disorder can be synergistically improved. The action mechanism is systematically illuminated through technical means such as proteomics, network pharmacology, molecular docking and the like. Glucose tolerance, insulin sensitivity and blood fat level of GDM rats can be remarkably improved, and no remarkable side effect exists.

The invention relates to an application of a Canxin oral liquid in preparation of an anti-aging drug, and belongs to the field of medicines. The Canxin oral liquid can tonify kidney and replenish essence, invigorate spleen and replenish qi, nourish blood and activate blood, and can effectively improve spleen and kidney deficiency, deficiency of qi and blood, soreness and weakness of waist and knees, insomnia and amnesia and weakness after illness caused by aging. Modern medicine proves that the Canxin oral liquid has the functions of improving blood sugar and blood fat levels of middle-aged and elderly diabetics and inhibiting occurrence and development of atherosclerotic plaques, animal experiment research proves that the Canxin oral liquid has a good treatment effect on aging model rats, can remarkably increase organ indexes and reduce oxidative stress and inflammation related factors, and has a good application prospect. The pathological forms of the liver and the kidney are improved, and a good anti-aging effect is achieved.

The invention relates to the technical field of biology, in particular to a probiotic composition for reducing blood sugar and application thereof.The probiotic composition comprises bifidobacterium longum subsp. Longum FMBL B241770LS and bifidobacterium animalis subsp. Lactis FMBL B24304AHDM which are preserved in the China Center for Type Culture Collection on September 21, 2024 with the preservation number of CCTCC NO: M 20241993 and preserved in the China Center for Type Culture Collection on November 18, 2024 with the preservation number of CCTCC NO: M 20241993 with the preservation number of CCTCC NO: M 20241993 with the preservation number of CCTCC NO: M 20241993 with the preservation number of CCTCC NO: M 20241993 with the the preservation number is CTCC (China Type Culture Collection) NO: M 20242505; the compound has a good inhibition effect on pathogenic bacteria, can obviously reduce oral glucose tolerance and insulin tolerance of T2DM mice, reduce abnormal fluctuation of postprandial blood glucose, reduce fasting blood glucose, fasting insulin level and blood fat level, relieve insulin resistance, effectively regulate intestinal flora imbalance and promote generation of short-chain fatty acid in intestinal tracts of the T2DM mice.

This invention belongs to the technical field of natural product active ingredients, specifically relating to a glycopeptide LBGP-I-b derived from wolfberry and its uses. The glycopeptide LBGP-I-b has an average molecular weight of 700–1000 Da, a polypeptide content of 70%–80%, and a polysaccharide content of 10%–20%. The sugar chains are composed of glucose residues, and the sugar chains are linked to the peptide chains via O-glycopeptide bonds. The glycopeptide has functions such as regulating lipid metabolism, lowering blood lipid levels, and improving liver function. The glycopeptide of this invention has a clear source and stable properties, and has good application prospects in the prevention and treatment of metabolic diseases such as metabolic-related fatty liver disease.

The invention discloses a composition containing dietary fiber and a preparation method thereof. The composition comprises components: 55-85 parts of dietary fiber, 0.1-7 parts of probiotics, 1-9 parts of red ginseng extract, 0.01-2 parts of phytosterols, 0.01-0.2 parts of L-carnitine, 0.05-0.8 parts of complex vitamins and 0.05-0.1 parts of mineral elements; the dietary fiber is a mixture of laver fiber, oat fiber, strawberry fiber, chickpea fiber and black rice fiber; the probiotics are a mixture of bifidobacterium longum, lactobacillus rhamnosus and lactobacillus acidophilus, and the live bacteria concentration of the probiotics is 6×10 8 CFU / g‑1×10 11 The composition can regulate the diversity of intestinal flora, enhance metabolism, reduce blood lipid levels, and has a good weight loss effect.

The present invention relates to an immunogenic compound comprising an ApoB100 epitope, an immunogenic composition comprising the same, and uses thereof. The immunogenic compound can be used to prevent or treat diseases caused by increased ApoB100 levels or increased lipid levels by inducing an immune response to the ApoB100 epitope. The immunogenic compound has a complementary mechanism to GIP-1R agonist obesity treatments, so their combined or concurrent administration can enhance weight loss and improve side effects associated with long-term administration of GIP-1R agonist obesity treatments by improving weight loss plateaus, delaying the yo-yo effect, and improving lean body mass reduction.

The invention provides application of plant hormone mitochondrial acid 5 in preparation of a medicine for treating myocardial injury caused by diabetes, and relates to the technical field of biological medicine. In the aspects of blood sugar and blood fat, the MA-5 reduces the blood sugar and blood fat levels of the mouse with the type 2 diabetes mellitus; in the aspect of cardiac injury involved by diabetes, MA-5 inhibits cardiac tissue fibrosis, improves mitochondrial injury, inhibits oxidative stress and reduces ROS (reactive oxygen species) generation. The MA-5 has the effects of stably reducing blood glucose and protecting diabetic cardiomyopathy. The composition is simple and clear; the taking is convenient; the price is low, and the like. Compared with the existing medicines for treating diabetes and diabetic cardiomyopathy, the chemical components of the MA-5 are simple and clear, the action mechanism of the MA-5 is easier to clarify in pharmacological research, and the quality of the medicines is easier to control in production. According to the application, a powerful experimental basis and a theoretical basis are provided for preventing and treating the type 2 diabetes mellitus and myocardial complications of the type 2 diabetes mellitus by the MA-5.

The invention discloses a low-energy wheat dietary fiber beverage and a preparation method thereof, wheat dietary fiber powder is used as a raw material, erythritol and stevioside are used as sweetening agents, konjaku flour is used as a natural thickening agent, and the wheat dietary fiber powder beverage is prepared through the links of blending, mixing, homogenizing, homogenizing, sterilizing and the like. The wheat dietary fiber beverage is mellow in taste and low in energy, can supplement enough dietary fibers for human bodies, has the functional characteristics of promoting digestion, controlling blood sugar and blood fat levels, resisting oxidation and the like, and can effectively solve the problems of poor drinking palatability, single taste and the like of wheat dietary fiber powder. The acceptability of the wheat dietary fiber powder is improved, and the requirements of the current public on sugar reduction and sugar control are met.

The invention relates to the technical field of microorganisms, in particular to lactococcus lactis subsp. Lactis JYLL-28 with a function of inhibiting fatty liver formation, bacterial powder and application, the lactococcus lactis subsp. Lactis JYLL-28 is preserved in the China General Microbiological Culture Collection Center on July 24, 2023, the preservation address is No. 3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No.1089. The lactococcus lactis subsp. Lactis JYLL-28 is JYLL-28. The preservation number is CGMCC (China General Microbiological Culture Collection Center) The lactococcus lactis subsp. Lactis JYLL-28 is used for inhibiting weight increase of rats, regulating and controlling the blood fat level, reducing the liver inflammation level and the serum endotoxin level, inhibiting fatty liver formation and preventing liver fatty degeneration, and has no toxic or side effect and a lasting curative effect.

The present invention relates to the field of microorganisms. The present invention provides a Pediococcus pentosaceus VB341 with lipid-lowering efficacy, a culture device and its application. The Pediococcus pentosaceus VB341 was deposited at the China Center for Type Culture Collection on March 8, 2024, with the deposit number CCTCC NO: M 2024433. The Pediococcus pentosaceus VB341 of the present invention has a strong ability to inhibit lipase activity, has strong stability in intestinal fluid and bile salts, can be used to inhibit fat hydrolysis, reduce blood lipid levels, help maintain a healthy blood lipid level, help control body fat and / or lose weight, and is not prone to generating resistance.